These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 1732634)

  • 1. Prediction of metastatic potential by cancer cell motility in the Dunning R-3327 prostatic adenocarcinoma in vivo model.
    Doyle GM; Sharief Y; Mohler JL
    J Urol; 1992 Feb; 147(2):514-8. PubMed ID: 1732634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic potential prediction by a visual grading system of cell motility: prospective validation in the Dunning R-3327 prostatic adenocarcinoma model.
    Mohler JL; Partin AW; Isaacs JT; Coffey DS
    Cancer Res; 1988 Aug; 48(15):4312-7. PubMed ID: 3390827
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of metastatic potential of aspirated cells from the Dunning R-3327 prostatic adenocarcinoma model.
    Doyle GM; Mohler JL
    J Urol; 1992 Mar; 147(3):756-9. PubMed ID: 1538478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic potential and substrate dependence of cell motility and attachment in the Dunning R-3327 rat prostatic adenocarcinoma model.
    Mohler JL; Levy F; Sharief Y
    Cancer Res; 1991 Dec; 51(24):6580-5. PubMed ID: 1742730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of metastatic potential by a new grading system of cell motility: validation in the Dunning R-3327 prostatic adenocarcinoma model.
    Mohler JL; Partin AW; Coffey DS
    J Urol; 1987 Jul; 138(1):168-70. PubMed ID: 3599207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Time lapse videomicroscopic identification of Dunning R-3327 adenocarcinoma and normal rat prostate cells.
    Mohler JL; Partin AW; Isaacs WB; Coffey DS
    J Urol; 1987 Mar; 137(3):544-7. PubMed ID: 3820394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flow cytometric assay of pinocytosis: correlation with membrane ruffling and metastatic potential in the Dunning R-3327 rat prostatic adenocarcinoma model.
    Mohler JL; Sharief Y
    Cytometry; 1993 Oct; 14(7):826-31. PubMed ID: 8243212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic instability assessed by sister chromatid exchange analysis in the Dunning R-3327 rat prostatic adenocarcinoma model and its relationship to metastatic potential.
    Sharief Y; Mohler JL
    Prostate; 1995 May; 26(5):247-52. PubMed ID: 7753709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1.
    Evans CP; Walsh DS; Kohn EC
    Int J Cancer; 1991 Aug; 49(1):109-13. PubMed ID: 1874563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early cell motility changes associated with an increase in metastatic ability in rat prostatic cancer cells transfected with the v-Harvey-ras oncogene.
    Partin AW; Isaacs JT; Treiger B; Coffey DS
    Cancer Res; 1988 Nov; 48(21):6050-3. PubMed ID: 3048653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell surface charge in predicting metastatic potential of aspirated cells from the Dunning rat prostatic adenocarcinoma model.
    Carter HB; Coffey DS
    J Urol; 1988 Jul; 140(1):173-5. PubMed ID: 3379685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fourier analysis of cell motility: correlation of motility with metastatic potential.
    Partin AW; Schoeniger JS; Mohler JL; Coffey DS
    Proc Natl Acad Sci U S A; 1989 Feb; 86(4):1254-8. PubMed ID: 2919174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biometric assessment of prostate cancer's metastatic potential.
    Cooper CR; Emmett N; Harris-Hooker S; Patterson R; Cooke DB
    World J Urol; 1994; 12(6):304-7. PubMed ID: 7881466
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI-TOF.
    Gretzer MB; Chan DW; van Rootselaar CL; Rosenzweig JM; Dalrymple S; Mangold LA; Partin AW; Veltri RW
    Prostate; 2004 Sep; 60(4):325-31. PubMed ID: 15264244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor.
    Isaacs JT; Yu GW; Coffey DS
    Invest Urol; 1981 Jul; 19(1):20-3. PubMed ID: 7251319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intermediate filament expression and the progression of prostatic cancer as studied in the Dunning R-3327 rat prostatic carcinoma system.
    Ramaekers FC; Verhagen AP; Isaacs JT; Feitz WF; Moesker O; Schaart G; Schalken JA; Vooijs GP
    Prostate; 1989; 14(4):323-39. PubMed ID: 2664736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in expression of oligosaccharide determinants by phenotypically distinct sublines of the Dunning 3327 rat prostate cancer.
    Abel PD; Foster CS; Tebbutt S; Williams G
    J Urol; 1990 Sep; 144(3):760-5. PubMed ID: 2388349
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of gonadotropin-releasing hormone receptor expression with the progression of prostate cancer in the Dunning rat adenocarcinoma sublines.
    Tieva A; Bergh A; Damber JE
    Acta Oncol; 2005; 44(3):299-303. PubMed ID: 16076703
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cancer cell motility-inhibitory protein in the Dunning adenocarcinoma model.
    Mohler JL; Broskie EN; Ranparia DJ; Sharief Y; Coleman WB; Smith GJ
    Cancer Res; 1992 Apr; 52(8):2349-52. PubMed ID: 1559238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro characterization of MAT LyLu: a Dunning rat prostate adenocarcinoma tumor subline.
    Wenger AS; Mickey DD; Hall M; Silverman LM; Mickey GH; Fried FA
    J Urol; 1984 Jun; 131(6):1232-6. PubMed ID: 6539387
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.